Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Mark Dransfield MD

Mark T Dransfield MD

Professor of Medicine and William C. Bailey MD Endowed Chair in Pulmonary Disease, Division of Pulmonary, Allergy and Critical Care, University of Alabama at Birmingham, AL

Disclosures

Dr. Dransfield served on the Data and Safety Monitoring Board (DSMB) for the SUMMIT study and has received consulting fees from GlaxoSmithKline.

Recent Contributions to PracticeUpdate:

  1. Initiation of Inhaled Long-Acting Bronchodilators in Patients With COPD and Increased Cardiovascular Risk
  2. Inhaled Beta2-Agonist/Corticosteroid Treatment Does Not Increase Cardiovascular Risk in Patients With COPD

Most Read This Week

Recently Updated